In light of our findings, one potential therapy to abrogate HNSCC metastasis would be an EphB4 agonist that targets the ephrin-binding pocket to activate EphB4 and inhibit ephrinB2. This evidence concerns the gene EPHB4 and head and neck squamous cell carcinoma.